| 摘要 |
Drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors containing the above compounds as the active ingredient, (in the formula, each symbol has the following meaning: D: pyrazolyl which may have 1 to 3 substituents selected from the group consisting of -Alk, -lower alkenyl, -lower alkynyl, -halogeno-lower alkyl, -Alk-cycloalkyl, -Alk-O-Alk, -cycloalkyl, -O-Alk, -COOH, -COO-Alk and -Hal, n: 0 or 1, B: phenylene, a nitrogen-containing, divalent, saturated ring group, or a monocyclic, divalent heteroaromatic ring group which may be substituted with Alk, X: -NR<SUP>1</SUP>-CR<SUP>2</SUP>R<SUP>3</SUP>-, -CR<SUP>2</SUP>R<SUP>3</SUP>-NR<SUP>1</SUP>-, -NR<SUP>1</SUP>-SO<SUB>2</SUB>-, -SO<SUB>2</SUB>-NR<SUP>1</SUP>- or -CR<SUP>4</SUP>-CR<SUP>5</SUP>-, and A: benzene ring which may have one or more substituents; mono-, di- or tricyclic fused heteroaryl which may have one or more substituents; cycloalkyl which may have one or more substituents; a nitrogen-containing, saturated ring group which may have one or more substituents; lower alkenyl which may have one or more substituents; lower alkynyl which may have one or more substituents; or Alk which may have one or more substituents).
|
